The Brain Has Its Own Anti-Opioid System That Reduces Opioid Receptor Numbers

Chronic infusion of the anti-opioid peptide NPFF reduced mu opioid receptor binding sites in rat brain without changing opioid peptide gene expression.

Rothman, R B et al.·Peptides·1993·Preliminary EvidenceAnimal StudyAnimal Study
RPEP-00273Animal StudyPreliminary Evidence1993RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Animal Study
Evidence
Preliminary Evidence
Sample
Not reported

What This Study Found

Chronic ICV NPFF (5 micrograms/h for 10 days) downregulated mu opioid binding sites. Dynorphin and enkephalin mRNA were unchanged.

Key Numbers

How They Did This

Rats received continuous ICV infusion of NPFF or saline for 10 days via osmotic minipumps. Mu opioid receptor binding measured by autoradiography. Dynorphin and enkephalin mRNA measured by in situ hybridization.

Why This Research Matters

The brain has its own anti-opioid system (NPFF) that can reduce opioid receptor numbers. This natural balancing mechanism could be harnessed for treating opioid addiction.

The Bigger Picture

If the brain naturally produces a peptide that reduces opioid sensitivity, this system could be involved in opioid tolerance and could be targeted therapeutically. Enhancing NPFF might help wean people off opioids; blocking it might enhance pain relief.

What This Study Doesn't Tell Us

Animal study with chronic brain infusion. Supraphysiological NPFF doses. Functional consequences of mu receptor downregulation not tested. Only one time point examined.

Questions This Raises

  • ?Could NPFF-based drugs help treat opioid addiction by naturally reducing opioid receptor sensitivity?
  • ?Is NPFF dysregulated in chronic pain patients?

Trust & Context

Key Stat:
Mu receptors downregulated 10 days of continuous NPFF infusion reduced mu opioid binding sites while leaving opioid peptide genes unchanged
Evidence Grade:
Preliminary — animal study with chronic brain infusion at potentially supraphysiological doses. Shows mechanism but clinical translation is distant.
Study Age:
Published in 1993 (33 years ago). NPFF and anti-opioid systems remain an active area of addiction and pain research.
Original Title:
Chronic intracerebroventricular infusion of the antiopioid peptide, Phe-Leu-Phe-Gln-Pro-Gln-Arg-Phe-NH2 (NPFF), downregulates mu opioid binding sites in rat brain.
Published In:
Peptides, 14(6), 1271-7 (1993)
Database ID:
RPEP-00273

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal StudyOne case or non-human subjects
This study

Tests effects in animals (usually mice or rats), not humans.

What do these levels mean? →

Frequently Asked Questions

What is an anti-opioid peptide?

NPFF is a peptide the brain naturally produces that works against the opioid system — it reduces opioid sensitivity and can block some morphine effects. It's part of the brain's balancing act to prevent the opioid system from becoming too dominant.

Could this help with opioid addiction?

Potentially. If we can harness the brain's natural anti-opioid system, it might help reduce opioid dependence. Alternatively, understanding it better could help prevent unwanted tolerance during pain treatment.

Read More on RethinkPeptides

Cite This Study

RPEP-00273·https://rethinkpeptides.com/research/RPEP-00273

APA

Rothman, R B; Brady, L S; Xu, H; Long, J B. (1993). Chronic intracerebroventricular infusion of the antiopioid peptide, Phe-Leu-Phe-Gln-Pro-Gln-Arg-Phe-NH2 (NPFF), downregulates mu opioid binding sites in rat brain.. Peptides, 14(6), 1271-7.

MLA

Rothman, R B, et al. "Chronic intracerebroventricular infusion of the antiopioid peptide, Phe-Leu-Phe-Gln-Pro-Gln-Arg-Phe-NH2 (NPFF), downregulates mu opioid binding sites in rat brain.." Peptides, 1993.

RethinkPeptides

RethinkPeptides Research Database. "Chronic intracerebroventricular infusion of the antiopioid p..." RPEP-00273. Retrieved from https://rethinkpeptides.com/research/rothman-1993-chronic-intracerebroventricular-infusion-of

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.